

Susan Halabi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9161296/publications.pdf>

Version: 2024-02-01

339
papers

23,494
citations

17776

65
h-index

9346

148
g-index

351
all docs

351
docs citations

351
times ranked

19852
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. <i>European Urology Oncology</i> , 2022, 5, 18-29.	2.6	31
2	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	2.0	15
3	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60.	1.3	12
4	Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 106-106.	0.8	1
5	Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 107-107.	0.8	5
6	Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 139-139.	0.8	0
7	HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 370-370.	0.8	0
8	Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2022, 82, 858-866.	1.2	10
9	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 762-769.	2.0	13
10	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN± ± Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.	3.2	8
11	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
12	Penalized weighted proportional hazards model for robust variable selection and outlier detection. <i>Statistics in Medicine</i> , 2022, , .	0.8	0
13	Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer. <i>Endocrine Oncology</i> , 2022, 2, R51-R64.	0.1	1
14	Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5044-5044.	0.8	1
15	Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4562-4562.	0.8	0
16	Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3008-3008.	0.8	7
17	Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5006-5006.	0.8	2
18	Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3114-3114.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).. Journal of Clinical Oncology, 2022, 40, 4521-4521.	0.8	0
20	Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. Clinical Trials, 2022, 19, 561-572.	0.7	2
21	Estimand framework: Are we asking the right questions? A case study in the solid tumor setting. Pharmaceutical Statistics, 2021, 20, 324-334.	0.7	8
22	Comparison of regression imputation methods of baseline covariates that predict survival outcomes. Journal of Clinical and Translational Science, 2021, 5, e40.	0.3	2
23	Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1271-1278.	0.4	10
24	Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).. Journal of Clinical Oncology, 2021, 39, 154-154.	0.8	0
25	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 3317-3328.	3.2	14
26	Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 157-157.	0.8	0
27	Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2021, 39, 39-39.	0.8	6
28	Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.. Journal of Clinical Oncology, 2021, 39, 89-89.	0.8	8
29	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncology, The, 2021, 22, 402-410.	5.1	79
30	Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Research, 2021, 19, 1040-1050.	1.5	17
31	On the design and the analysis of stratified biomarker trials in the presence of measurement error. Statistics in Medicine, 2021, 40, 2783-2799.	0.8	0
32	A semiparametric modeling approach for analyzing clinical biomarkers restricted to limits of detection. Pharmaceutical Statistics, 2021, 20, 1061-1073.	0.7	0
33	In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions. European Urology Open Science, 2021, 26, 14-17.	0.2	2
34	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 4077-4088.	3.2	21
35	Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 5057-5057.	0.8	4
36	Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset?. European Urology, 2021, 79, 663-664.	0.9	0

#	ARTICLE	IF	CITATIONS
37	A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2954-2965.	2.0	21
38	Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2443-2451.	0.8	97
39	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
40	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021, 39, 2486-2496.	0.8	26
41	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021, 30, 47-62.	0.2	2
42	Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 298-307.	0.2	24
43	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2926-2937.	0.8	36
44	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021, 155, 165-171.	0.5	11
45	Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2021, 19, 64-72.	0.1	4
46	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2134330.	2.8	32
47	Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes. <i>Lifetime Data Analysis</i> , 2020, 26, 266-291.	0.4	4
48	Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 66-73.	2.0	9
49	Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 79.e15-79.e22.	0.8	21
50	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 225-239.	1.5	18
51	Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. <i>Oncologist</i> , 2020, 25, e405-e411.	1.9	2
52	Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 222-229.e2.	0.9	5
53	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Targeted Oncology</i> , 2020, 15, 743-750.	1.7	25
54	Best (but oft-forgotten) practices: sample size and power calculation for a dietary intervention trial with episodically consumed foods. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 920-925.	2.2	1

#	ARTICLE	IF	CITATIONS
55	Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3042-3050.	0.8	60
56	Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Targeted Oncology</i> , 2020, 15, 733-741.	1.7	25
57	Score and deviance residuals based on the full likelihood approach in survival analysis. <i>Pharmaceutical Statistics</i> , 2020, 19, 940-954.	0.7	3
58	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
59	Pan-cancer prognostic models of clinical outcomes: statistical exercise or clinical tools?. <i>Annals of Oncology</i> , 2020, 31, 1427-1429.	0.6	2
60	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	1.5	42
61	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa003.	1.4	1
62	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	0.8	37
63	Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2020, 4, 757-766.	1.5	52
64	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
65	Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 930-941.	0.6	14
66	Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4637-4637.	0.8	9
67	Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5561-5561.	0.8	4
68	Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with <i>BRAF</i> V600E mutations: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 122-122.	0.8	10
69	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with <i>ERBB2</i> amplification or overexpression: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 132-132.	0.8	38
70	Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 133-133.	0.8	28
71	AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.. <i>Journal of Clinical Oncology</i> , 2020, 38, 184-184.	0.8	1
72	Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 96-96.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2020, 38, 5567-5567.	0.8	2
74	Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.. Journal of Clinical Oncology, 2020, 38, 183-183.	0.8	1
75	Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 84-84.	0.8	0
76	Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 147-147.	0.8	0
77	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist, 2019, 24, 1497-1501.	1.9	22
78	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. Journal of Clinical Oncology, 2019, 37, 2184-2186.	0.8	7
79	Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate, 2019, 79, 1752-1761.	1.2	1
80	Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	3.4	288
81	On the Use of Min-Max Combination of Biomarkers to Maximize the Partial Area under the ROC Curve. Journal of Probability and Statistics, 2019, 2019, 1-13.	0.3	3
82	Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. PLoS ONE, 2019, 14, e0216934.	1.1	14
83	A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. JNCI Cancer Spectrum, 2019, 3, pkz002.	1.4	52
84	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129.	0.8	267
85	Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer. European Urology Focus, 2019, 5, 137-143.	1.6	6
86	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. Journal of Clinical Oncology, 2019, 37, 403-410.	0.8	83
87	Advancing Precision Oncology Through Biomarker-Driven Trials: Theory vs. Practice. Chance, 2019, 32, 23-31.	0.1	2
88	Improved Reporting in Abstracts When Uncertainty Is Inevitable. JAMA Network Open, 2019, 2, e1917543.	2.8	0
89	Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern Oncology. JCO Precision Oncology, 2019, 3, 1-12.	1.5	20
90	Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2019, 3, 1-8.	1.5	46

#	ARTICLE	IF	CITATIONS
91	Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 309-316.	2.0	14
92	Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reported <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Cancer Research</i> , 2019, 79, CT135-CT135.	0.4	2
93	Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) with <i>FLT-3</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Cancer Research</i> , 2019, 79, CT146-CT146.	0.4	2
94	Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1014-1014.	0.8	29
95	CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4503-4503.	0.8	35
96	Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5008-5008.	0.8	31
97	CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5079-5079.	0.8	9
98	Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9041-9041.	0.8	7
99	Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 186-186.	0.8	2
100	Developing and Validating Prognostic Models of Clinical Outcomes. , 2019, , 347-374.		2
101	External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5022-5022.	0.8	0
102	Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16579-e16579.	0.8	0
103	PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5021-5021.	0.8	0
104	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018, 94, 115-125.	1.3	280
105	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
106	Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. <i>Annals of Oncology</i> , 2018, 29, 23-25.	0.6	6
107	Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S100.	0.4	0
108	Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	98

#	ARTICLE	IF	CITATIONS
109	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 812-818.	0.8	85
110	Combined performance of screening and variable selection methods in ultra-high dimensional data in predicting time-to-event outcomes. <i>Diagnostic and Prognostic Research</i> , 2018, 2, .	0.8	12
111	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	3.2	14
112	Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2532.	0.8	27
113	The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5004-5004.	0.8	8
114	Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA5005-LBA5005.	0.8	3
115	Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA5009-LBA5009.	0.8	24
116	Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11-11.	0.8	3
117	Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 582-582.	0.8	7
118	Statistical Considerations for Developing and Validating Prognostic Models of Clinical Outcomes. , 2018, , .		1
119	Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.. <i>Journal of Clinical Oncology</i> , 2018, 36, 160-160.	0.8	1
120	Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5029-5029.	0.8	0
121	A simple method for deriving the confidence regions for the penalized Cox's model via the minimand perturbation. <i>Communications in Statistics - Theory and Methods</i> , 2017, 46, 4791-4808.	0.6	7
122	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 81, 228-236.	1.3	76
123	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6802-6811.	3.2	69
124	Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. <i>Journal of Surgical Oncology</i> , 2017, 116, 969-982.	0.8	97
125	Comparison of futility monitoring guidelines using completed phase III oncology trials. <i>Clinical Trials</i> , 2017, 14, 48-58.	0.7	13
126	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 591-597.	0.8	584

#	ARTICLE	IF	CITATIONS
127	Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. <i>Prostate</i> , 2017, 77, 385-395.	1.2	6
128	Reply to B. Rini et al and S. Buti et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1859-1860.	0.8	1
129	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3097-3104.	0.8	327
130	Title is missing!. , 2017, , .		1
131	Title is missing!. , 2017, , .		4
132	Title is missing!. , 2017, , .		3
133	Title is missing!. , 2017, , .		7
134	Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5034-5034.	0.8	0
135	Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5067-5067.	0.8	0
136	Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4522-4522.	0.8	1
137	High Dimensional Variable Selection with Error Control. <i>BioMed Research International</i> , 2016, 2016, 1-11.	0.9	8
138	CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. <i>Annals of Oncology</i> , 2016, 27, vi566.	0.6	11
139	Critical Assessment of Clinical Prognostic Tools in Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2753-2761.	0.7	44
140	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. <i>Clinical Cancer Research</i> , 2016, 22, 4890-4900.	3.2	46
141	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 370-374.	157.7	280
142	Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP). <i>Annals of Oncology</i> , 2016, 27, vi243.	0.6	9
143	Residential metal contamination and potential health risks of exposure in adobe brick houses in Potos�, Bolivia. <i>Science of the Total Environment</i> , 2016, 562, 237-246.	3.9	10
144	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 378-388.	5.1	327

#	ARTICLE	IF	CITATIONS
145	A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 100-106.	2.0	14
146	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
147	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.	0.8	332
148	Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 40-45.	2.0	6
149	Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5023-5023.	0.8	4
150	Phase Ib trial of cabazitaxel and tasquinimod in men with heavily pretreated metastatic castration resistant prostate cancer (mCRPC): The CATCH trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 190-190.	0.8	1
151	Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 275-275.	0.8	0
152	Impact of therapy on gene expression in high-risk prostate cancer (PCA) treated with neoadjuvant docetaxel and androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8-8.	0.8	0
153	Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS5093-TPS5093.	0.8	0
154	Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance). , 2016, , .		0
155	MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE). <i>Journal of Urology</i> , 2015, 193, .	0.2	1
156	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). <i>EBioMedicine</i> , 2015, 2, 1814-1820.	2.7	13
157	A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events. <i>Pharmaceutical Statistics</i> , 2015, 14, 273-283.	0.7	0
158	Making Progress on Progression in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1322-1324.	0.8	3
159	Refining Prognosis in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1576-1589.	0.5	31
160	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015, 107, djv261.	3.0	53
161	Mercury hair levels and factors that influence exposure for residents of Huancavelica, Peru. <i>Environmental Geochemistry and Health</i> , 2015, 37, 507-514.	1.8	12
162	Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 110.e1-110.e9.	0.8	17

#	ARTICLE	IF	CITATIONS
163	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015, 26, 1589-1604.	0.6	279
164	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). <i>Cancer</i> , 2015, 121, 1025-1031.	2.0	32
165	Independent data monitoring committees: An update and overview. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 143-148.	0.8	13
166	Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?. <i>Cancer</i> , 2015, 121, 1906-1906.	2.0	0
167	Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome. <i>Communications in Statistics - Theory and Methods</i> , 2015, 44, 275-285.	0.6	2
168	Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4507-4507.	0.8	11
169	The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5000-5000.	0.8	25
170	Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5025-5025.	0.8	6
171	A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy (RT) in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2015, 33, 35-35.	0.8	0
172	Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2014, 120, 52-60.	2.0	40
173	Adjusting for misclassification in a stratified biomarker clinical trial. <i>Statistics in Medicine</i> , 2014, 33, 3100-3113.	0.8	17
174	Reply to F. Valcamonico et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3685-3685.	0.8	0
175	PD27-09 MANAGEMENT OF RECURRENT PROSTATE CANCER AFTER RADIOTHERAPY: LONG-TERM RESULTS FROM CALGB 9687, A CONTEMPORARY PROSPECTIVE MULTI-INSTITUTIONAL SALVAGE PROSTATECTOMY SERIES. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
176	Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 1143-1150.	0.8	217
177	Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 671-677.	0.8	410
178	The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5002-5002.	0.8	6
179	Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4532-4532.	0.8	1
180	Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).. <i>Journal of Clinical Oncology</i> , 2014, 32, e16061-e16061.	0.8	0

#	ARTICLE	IF	CITATIONS
181	A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).. Journal of Clinical Oncology, 2014, 32, 9612-9612.	0.8	0
182	Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE)., 2014, , .		0
183	Reply to M.A. Khattak et al. Journal of Clinical Oncology, 2013, 31, 972-973.	0.8	0
184	On model specification and selection of the Cox proportional hazards model. Statistics in Medicine, 2013, 32, 4609-4623.	0.8	8
185	A Phase II Trial of Tamsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer. Clinical Genitourinary Cancer, 2013, 11, 397-406.	0.9	52
186	Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. Journal of the National Cancer Institute, 2013, 105, 1729-1737.	3.0	150
187	Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy. Journal of the National Cancer Institute, 2013, 105, 499-503.	3.0	79
188	Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy. Journal of Clinical Oncology, 2013, 31, 3944-3950.	0.8	83
189	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer. Cancer, 2013, 119, 3636-3643.	2.0	17
190	A survey of clinical prediction tools in colorectal and lung cancers and melanoma.. Journal of Clinical Oncology, 2013, 31, 1592-1592.	0.8	13
191	Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, 5031-5031.	0.8	3
192	A phase II trial of tamsirolimus in men with castration-resistant metastatic prostate cancer.. Journal of Clinical Oncology, 2013, 31, 105-105.	0.8	1
193	Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).. Journal of Clinical Oncology, 2013, 31, 27-27.	0.8	3
194	Residential Mercury Contamination in Adobe Brick Homes in Huancavelica, Peru. PLoS ONE, 2013, 8, e75179.	1.1	13
195	Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints. Journal of Biometrics & Biostatistics, 2013, 01, 15.	4.0	3
196	A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.. Journal of Clinical Oncology, 2013, 31, 24-24.	0.8	0
197	ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, TPS4590-TPS4590.	0.8	4
198	Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin. Journal of Clinical Oncology, 2012, 30, 3402-3407.	0.8	138

#	ARTICLE	IF	CITATIONS
199	Design Issues in Randomized Phase II/III Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 667-671.	0.8	63
200	Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. <i>Pain Medicine</i> , 2012, 13, 1417-1424.	0.9	17
201	Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease. <i>Statistics in Medicine</i> , 2012, 31, 29-44.	0.8	0
202	Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401. <i>Journal of Clinical Oncology</i> , 2012, 30, 1534-1540.	0.8	436
203	Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy. <i>Cancer</i> , 2012, 118, 4139-4147.	2.0	18
204	Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2012, 61, 549-559.	0.9	159
205	Estimations of historical atmospheric mercury concentrations from mercury refining and present-day soil concentrations of total mercury in Huancavelica, Peru. <i>Science of the Total Environment</i> , 2012, 426, 146-154.	3.9	16
206	Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4655-4655.	0.8	2
207	Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 129-129.	0.8	2
208	Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 200-200.	0.8	4
209	The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4667-4667.	0.8	0
210	External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4592-4592.	0.8	0
211	Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4515-4515.	0.8	21
212	Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809. <i>European Journal of Cancer</i> , 2011, 47, 683-689.	1.3	86
213	Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia. <i>Atmospheric Environment</i> , 2011, 45, 7619-7626.	1.9	35
214	A min-max combination of biomarkers to improve diagnostic accuracy. <i>Statistics in Medicine</i> , 2011, 30, 2005-2014.	0.8	51
215	A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer. <i>Cancer</i> , 2011, 117, 526-533.	2.0	70
216	Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer. <i>Cancer</i> , 2011, 117, 5579-5588.	2.0	29

#	ARTICLE	IF	CITATIONS
217	Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2011, 29, 189-189.	0.8	6
218	Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium.. Journal of Clinical Oncology, 2011, 29, 4664-4664.	0.8	0
219	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunology, Immunotherapy, 2010, 59, 663-674.	2.0	279
220	The Importance of Identifying and Validating Prognostic Factors in Oncology. Seminars in Oncology, 2010, 37, e9-e18.	0.8	56
221	Combination External Beam Radiation and Brachytherapy Boost with Androgen Suppression for Treatment of Intermediate-risk Prostate Cancer: Long-term Results of CALGB 99809. International Journal of Radiation Oncology Biology Physics, 2010, 78, S146.	0.4	0
222	Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Annals of Oncology, 2010, 21, 312-318.	0.6	45
223	Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206. Journal of Clinical Oncology, 2010, 28, 2137-2143.	0.8	746
224	Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 942-949.	3.0	55
225	A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer. Clinical Cancer Research, 2010, 16, 3057-3066.	3.2	66
226	Bevacizumab and Everolimus in Renal Cancer: A Rational Way Forward. Journal of Clinical Oncology, 2010, 28, e692-e693.	0.8	5
227	The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. European Journal of Cancer, 2010, 46, 517-525.	1.3	118
228	The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate Cancer. Urology, 2010, 75, 623-629.	0.5	11
229	Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study.. Journal of Clinical Oncology, 2010, 28, TPS249-TPS249.	0.8	2
230	A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.. Journal of Clinical Oncology, 2010, 28, LBA4511-LBA4511.	0.8	87
231	Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials. Journal of the National Cancer Institute, 2009, 101, 256-266.	3.0	429
232	Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 2766-2771.	0.8	99
233	The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2009, 12, 88-93.	2.0	29
234	A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Annals of Oncology, 2009, 20, 1074-1079.	0.6	104

#	ARTICLE	IF	CITATIONS
235	Arsenic Trioxide in Recurrent Urothelial Cancer: A Cancer and Leukemia Group B Phase II Trial (CALGB) Tj ETQq1 1 0,784314 rgBT /Over	0.9	5
236	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. European Urology Supplements, 2009, 8, 738-746.	0.1	5
237	PATIENT SATISFACTION WITH OBSERVATION OR HORMONAL THERAPY AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) AFTER BIOCHEMICAL FAILURE IN MEN WITH PROSTATE CANCER: RESULTS FROM THE COMPARE REGISTRY. Journal of Urology, 2009, 181, 90-90.	0.2	0
238	Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer. Cancer, 2008, 113, 3137-3145.	2.0	13
239	Tumor Volume Changes on 1.5 Tesla Endorectal MRI During Neoadjuvant Androgen Suppression Therapy for Higher-Risk Prostate Cancer and Recurrence in Men Treated Using Radiation Therapy Results of the Phase II CALGB 9682 Study. International Journal of Radiation Oncology Biology Physics, 2008, 71, 9-15.	0.4	14
240	Combination External Beam Radiation and Brachytherapy Boost With Androgen Suppression for Treatment of Intermediate-Risk Prostate Cancer: An Initial Report of CALGB 99809. International Journal of Radiation Oncology Biology Physics, 2008, 72, 814-819.	0.4	18
241	A Phase II Study of Estramustine, Docetaxel, and Exisulind in Patients with Hormone- Refractory Prostate Cancer: Results of Cancer and Leukemia Group B Trial 90004. Clinical Genitourinary Cancer, 2008, 6, 110-116.	0.9	10
242	p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology, 2008, 71, 933-937.	0.5	21
243	Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 300-307.	0.8	2
244	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 2008, 26, 1148-1159.	0.8	1,960
245	MANAGEMENT OF RECURRENT PROSTATE CANCER AFTER RADIOTHERAPY: RESULTS FROM CALGB 9687, A CONTEMPORARY PROSPECTIVE MULTINSTITUTIONAL SALVAGE RADICAL PROSTATECTOMY SERIES. Journal of Urology, 2008, 179, 647-647.	0.2	2
246	EFFECTS OF AGE, HEALTH-RELATED QUALITY OF LIFE, AND EDUCATION LEVEL ON MANAGEMENT AFTER BIOCHEMICAL FAILURE WITH WATCHFUL WAITING VERSUS HORMONAL THERAPY IN MEN WITH PROSTATE CANCER: RESULTS FROM THE COMPARE REGISTRY. Journal of Urology, 2008, 179, 109-109.	0.2	1
247	Hormonal Risk Factors for Ovarian Cancer in Premenopausal and Postmenopausal Women. American Journal of Epidemiology, 2008, 167, 1059-1069.	1.6	99
248	Cyclin E Overexpression in Epithelial Ovarian Cancer Characterizes an Etiologic Subgroup. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 585-593.	1.1	34
249	Flexible Frames and Control Sampling in Case-Control Studies. American Statistician, 2008, 62, 307-313.	0.9	5
250	Circulating Levels of Inflammatory Cytokines and Risk of Colorectal Adenomas. Cancer Research, 2008, 68, 323-328.	0.4	260
251	Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. Journal of Clinical Oncology, 2008, 26, 5422-5428.	0.8	874
252	Use of Nonsteroidal Antiinflammatory Drugs and Distal Large Bowel Cancer in Whites and African Americans. American Journal of Epidemiology, 2008, 168, 1292-1300.	1.6	11

#	ARTICLE	IF	CITATIONS
253	Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. <i>Annals of Oncology</i> , 2008, 19, 946-950.	0.6	45
254	Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2544-2549.	0.8	173
255	Sample size selection in clinical trials when population means are subject to a partial order: one-sided ordered alternatives. <i>Journal of Applied Statistics</i> , 2008, 35, 583-600.	0.6	3
256	The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5074-5074.	0.8	0
257	Second-line chemotherapy for advanced hormone-refractory prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 118-22, 127-32.	0.3	23
258	ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary. <i>Journal of Oncology Practice</i> , 2007, 3, 236-236.	2.5	2
259	Trinucleotide Repeat Polymorphisms in the Androgen Receptor Gene and Risk of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 473-480.	1.1	51
260	Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study. <i>Clinical Cancer Research</i> , 2007, 13, 2030-2037.	3.2	85
261	American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2464-2472.	0.8	393
262	The Impact of Prior Radical Prostatectomy in Men With Metastatic Castration Recurrent Prostate Cancer: A Pooled Analysis of 9 Cancer and Leukemia Group B Trials. <i>Journal of Urology</i> , 2007, 177, 531-534.	0.2	21
263	Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. <i>Cancer</i> , 2007, 110, 1478-1484.	2.0	61
264	p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S333.	0.4	1
265	A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. <i>BJU International</i> , 2007, 101, 071008070648004-???	1.3	40
266	207: Management of Prostate-specific Antigen (PSA) Recurrence after Initial Definitive Local Therapy for Prostate Cancer: Updated Results from the Compare Registry. <i>Journal of Urology</i> , 2007, 177, 70-70.	0.2	0
267	Clinical Outcomes by Age in Men With Hormone Refractory Prostate Cancer: A Pooled Analysis of 8 Cancer and Leukemia Group B (CALGB) Studies. <i>Journal of Urology</i> , 2006, 176, 81-86.	0.2	21
268	Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone- Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480. <i>Clinical Genitourinary Cancer</i> , 2006, 4, 269-274.	0.9	38
269	Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 778-785.	2.0	40
270	2230. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S337-S338.	0.4	0

#	ARTICLE	IF	CITATIONS
271	A phase II study of gemcitabine and capecitabine in metastatic renal cancer. <i>Cancer</i> , 2006, 107, 1273-1279.	2.0	68
272	Analgesic Drug Use and Risk of Ovarian Cancer. <i>Epidemiology</i> , 2006, 17, 104-107.	1.2	68
273	Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee. <i>Clinical Cancer Research</i> , 2006, 12, 3596s-3600s.	3.2	2
274	205: Variations in Prostate Cancer Care According to Race, Geographic Region, and Literacy: Initial Findings from the Compare Registry. <i>Journal of Urology</i> , 2006, 175, 66-67.	0.2	0
275	1596: Choices for Definitive Treatment of Early-Stage Prostate Cancer: Results from the Compare Registry. <i>Journal of Urology</i> , 2006, 175, 514-514.	0.2	0
276	Antidepressant Medication Use for and Risk of Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2005, 105, 725-730.	1.2	18
277	Notice of a Second Report of the Same Case. <i>Obstetrics and Gynecology</i> , 2005, 105, 673.	1.2	3
278	Menopausal hormones and risk of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 76-82.	0.7	30
279	Transforming growth factor β^2 receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. <i>Gynecologic Oncology</i> , 2005, 97, 543-549.	0.6	17
280	Anthropometric Measurements and Epithelial Ovarian Cancer Risk in African-American and White women. <i>Cancer Causes and Control</i> , 2005, 16, 955-963.	0.8	41
281	The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480. <i>Clinical Cancer Research</i> , 2005, 11, 1815-1820.	3.2	152
282	Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study. <i>Clinical Cancer Research</i> , 2005, 11, 8109-8113.	3.2	27
283	Elevated Body Mass Index Predicts for Longer Overall Survival Duration in Men With Metastatic Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2434-2435.	0.8	25
284	Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. <i>Urology</i> , 2005, 66, 386-391.	0.5	89
285	Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583). <i>Journal of Clinical Oncology</i> , 2004, 22, 1025-1033.	0.8	464
286	Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 537-556.	0.8	189
287	Cancer and Leukemia Group B 90206. <i>Clinical Cancer Research</i> , 2004, 10, 2584-2586.	3.2	158
288	Sample size determination for comparing several survival curves with unequal allocations. <i>Statistics in Medicine</i> , 2004, 23, 1793-1815.	0.8	26

#	ARTICLE	IF	CITATIONS
289	Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. <i>Cancer</i> , 2004, 101, 370-378.	2.0	101
290	Impact of race on survival in men with metastatic hormone-refractory prostate cancer. <i>Urology</i> , 2004, 64, 212-217.	0.5	31
291	9-Nitrocampthecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 398-403.	0.8	7
292	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. <i>Blood</i> , 2004, 104, 810-810.	0.6	5
293	Overview of bladder cancer trials in the Cancer and Leukemia Group B. <i>Cancer</i> , 2003, 97, 2090-2098.	2.0	33
294	A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2003, 98, 2592-2598.	2.0	88
295	A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 883-890.	13.9	1,095
296	Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1232-1237.	0.8	646
297	Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer. <i>Evidence-Based Medicine</i> , 2003, 8, 179-179.	0.6	0
298	Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663. <i>Journal of Clinical Oncology</i> , 2003, 21, 2673-2678.	0.8	343
299	Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Metastatic Prostate Cancer: A Nested Study Within CALGB 9583. <i>Journal of Clinical Oncology</i> , 2003, 21, 490-495.	0.8	54
300	Analysis of Survival Data with Missing Measurements of a Time-Dependent Binary Covariate. <i>Journal of Biopharmaceutical Statistics</i> , 2003, 13, 253-270.	0.4	3
301	A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 579-580.	0.8	2
302	No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 226-7.	1.1	10
303	Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480. <i>Journal of Clinical Oncology</i> , 2002, 20, 3369-3375.	0.8	50
304	Effects of a mammography decision-making intervention at 12 and 24 months. <i>American Journal of Preventive Medicine</i> , 2002, 22, 247-257.	1.6	132
305	A Tailored Intervention to Aid Decisionmaking About Hormone Replacement Therapy. <i>American Journal of Public Health</i> , 2002, 92, 1112-1114.	1.5	40
306	Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2002, 94, 665-672.	2.0	14

#	ARTICLE	IF	CITATIONS
307	Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). <i>Cancer Causes and Control</i> , 2002, 13, 807-811.	0.8	50
308	Age at natural menopause and the risk of epithelial ovarian cancer. <i>Obstetrics and Gynecology</i> , 2001, 98, 85-90.	1.2	38
309	Women's Interest in Chemoprevention for Breast Cancer. <i>Archives of Internal Medicine</i> , 2001, 161, 1639.	4.3	45
310	Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Men With Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3025-3028.	0.8	52
311	Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780. <i>Journal of Clinical Oncology</i> , 2001, 19, 2509-2516.	0.8	308
312	The short-term impact of tailored mammography decision-making interventions. <i>Patient Education and Counseling</i> , 2001, 43, 271-287.	1.0	80
313	Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial. <i>Cancer</i> , 2001, 91, 1040-1045.	2.0	40
314	Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second-Line Hormonal Therapy (CALGB 9181). <i>Prostate Journal</i> , 2001, 3, 18-25.	0.2	5
315	A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. <i>Cancer</i> , 2000, 88, 825-834.	2.0	70
316	The impact of abnormal mammograms on psychosocial outcomes and subsequent screening. <i>Psycho-Oncology</i> , 2000, 9, 402-410.	1.0	62
317	Can tailored interventions increase mammography use among HMO women?. <i>American Journal of Preventive Medicine</i> , 2000, 18, 1-10.	1.6	95
318	Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. <i>Obstetrics and Gynecology</i> , 2000, 95, 119-127.	1.2	30
319	Maximizing the Motivational Impact of Feedback of Lung Cancer Susceptibility on Smokers' Desire to Quit. <i>Journal of Health Communication</i> , 2000, 5, 229-241.	1.2	39
320	A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. , 2000, 88, 825.		4
321	The impact of abnormal mammograms on psychosocial outcomes and subsequent screening. , 2000, 9, 402.		7
322	Factors associated with repeat mammography screening. <i>Journal of Family Practice</i> , 2000, 49, 1104-12.	0.2	62
323	Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 1999, 17, 3461-3467.	0.8	931
324	Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 2506-2506.	0.8	853

#	ARTICLE	IF	CITATIONS
325	Confusion about Mammography: Prevalence and Consequences. <i>Journal of Women's Health and Gender-Based Medicine</i> , 1999, 8, 509-520.	1.7	22
326	Attitudes and Knowledge Associated with being Undecided about Hormone Replacement Therapy: Results from a Community Sample. <i>Women's Health Issues</i> , 1999, 9, 330-337.	0.9	4
327	p53, c-erbB2, and PCNA Status in Benign, Proliferative, and Malignant Ovarian Surface Epithelial Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 310-316.	1.2	21
328	Validation of a Breast Cancer Risk Assessment Model in Women With a Positive Family History. <i>Journal of the National Cancer Institute</i> , 1994, 86, 620-625.	3.0	162
329	Factors associated with perceived risk of breast cancer among women attending a screening program. <i>Breast Cancer Research and Treatment</i> , 1993, 28, 137-144.	1.1	89
330	The Texas Breast Screening Project: Part II. <i>Southern Medical Journal</i> , 1993, 86, 391-396.	0.3	14
331	The Texas Breast Screening Project: Part I. <i>Southern Medical Journal</i> , 1993, 86, 385-390.	0.3	6
332	Incidence of Autoimmune Disease in Patients after Breast Reconstruction with Silicone Gel Implants Versus Autogenous Tissue. <i>Annals of Plastic Surgery</i> , 1993, 31, 1-6.	0.5	77
333	Reliability and Validity of Self and Proxy Reporting of Morbidity Data: A Case Study from Beirut, Lebanon. <i>International Journal of Epidemiology</i> , 1992, 21, 607-612.	0.9	40
334	Low incidence of familial breast cancer among Hispanic women. <i>Cancer Causes and Control</i> , 1992, 3, 377-382.	0.8	21
335	Breast cancer screening behaviors and attitudes in three racial/ethnic groups. <i>Cancer</i> , 1992, 69, 165-174.	2.0	134
336	Epidemiology of primary health problems in Beirut.. <i>Journal of Epidemiology and Community Health</i> , 1989, 43, 315-318.	2.0	12
337	HOSPITAL VISITORS AS CONTROLS. <i>American Journal of Epidemiology</i> , 1988, 127, 404-406.	1.6	9
338	Measures of social class based on education for use in health studies in developing countries.. <i>Journal of Epidemiology and Community Health</i> , 1987, 41, 173-179.	2.0	26
339	Perception of consanguineous marriages and their genetic effects among a sample of couples from beirut. <i>American Journal of Medical Genetics Part A</i> , 1986, 25, 299-306.	2.4	46